Health Canada Advises Héma-Québec to put a Hold on Specific Blood Products
MONTREAL, QUEBEC, December 18, 1998 - Health Canada has advised Héma-Québec to put a hold on specific blood products supplied by Bayer Corporation. Health Canada and the United States Food and Drug Administration are investigating information related to a U.S. plasma donor who contributed to these plasma products. This donor has been tentatively diagnosed with the classic form (not the new variant) of Creutzfeldt-Jacob Disease (CJD). Currently there is no epidemiological evidence that CJD is transmitted through blood.
These are precautionary measures pending further information. This is not a recall.
The products involved are:
BayHep : Hepatitis B Immune Globulin
Gamimune-SD : Intravenous Immune Globulin
Plasbumin : Albumin
Specific batches of Kogenate : Recombinant Factor VIII
Héma-Québec has advised hospitals to put a hold on their stocks of these products and to use alternatives, where possible. Héma-Québec is not instructing hospitals to return the products in question.
Héma-Québec's mission includes providing Quebecers with adequate quantities of safe, high-quality blood components, derivatives and substitutes to meet the needs of hospitals and to provide recognized expertise and specialized services in immuno-hematology.